T1	intervention 74 81	DA-3031
T2	control 127 137	filgrastim
T3	eligibility 141 194	patients receiving TAC chemotherapy for breast cancer
T4	total-participants 457 469	Seventy-four
T5	eligibility 470 597	patients with breast cancer who were receiving combination chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC)
T7	outcome 1181 1218	nadir absolute neutrophil count (ANC)
T8	outcome 1317 1337	time to ANC recovery
T9	outcome 1453 1464	Serious AEs
T10	cv-bin-abs 1477 1480	six
T12	cv-bin-percent 1482 1488	15.8 %
T11	iv-bin-abs 1527 1530	ten
T13	iv-bin-percent 1532 1538	27.8 %
T15	iv-cont-mean 1235 1245	161.75/mm3
T6	cv-cont-mean 1220 1230	154.34/mm3
T14	cv-cont-mean 1339 1344	10.03
T16	cv-cont-sd 1347 1351	0.75
T17	iv-cont-mean 1356 1360	9.83
T18	iv-cont-sd 1363 1372	1.56 days
T19	outcome 850 902	mean duration of grade 4 (G4) neutropenia in cycle 1
T20	cv-cont-mean 907 911	2.08
T21	cv-cont-sd 914 923	0.85 days
T22	iv-cont-mean 953 957	2.28
T23	iv-cont-sd 960 969	1.14 days
